Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.

@article{Sun2009Phase2C,
  title={Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-na{\"i}ve adults.},
  author={Wellington Sun and Dennis Cunningham and Steven S. Wasserman and Judith J. Perry and J. Robert Putnak and Kenneth H. Eckels and David W. Vaughn and Stephen J Thomas and Niranjan Kanesa-thasan and Bruce L. Innis and Robert D Edelman},
  journal={Human vaccines},
  year={2009},
  volume={5 1},
  pages={33-40}
}
Sixteen dose formulations of our live-attenuated tetravalent dengue virus vaccines (TDV) were previously evaluated for safety and immunogenicity. Two of the sixteen candidate TDV formulations (Formulations 13 and 14) were selected for further evaluation. A new TDV formulation, Formulation 17, using a higher primary dog kidney (PDK) cell passage Dengue-1… CONTINUE READING